Utilisation review of clopidogrel: Are they used under the FDA-approved indications?

Niruntraporn, Surachet, Chaiyakunapruk, Nathorn, Nathisuwan, Surakit and Thamlikitkul, Visanu (2007) Utilisation review of clopidogrel: Are they used under the FDA-approved indications?. Pharmacoepidemiology and Drug Safety, 16 9: 1031-1037. doi:10.1002/pds.1429

Author Niruntraporn, Surachet
Chaiyakunapruk, Nathorn
Nathisuwan, Surakit
Thamlikitkul, Visanu
Title Utilisation review of clopidogrel: Are they used under the FDA-approved indications?
Journal name Pharmacoepidemiology and Drug Safety   Check publisher's open access policy
ISSN 1053-8569
Publication date 2007-09-01
Sub-type Article (original research)
DOI 10.1002/pds.1429
Open Access Status
Volume 16
Issue 9
Start page 1031
End page 1037
Total pages 7
Place of publication West Sussex, United Kingdom
Publisher John Wiley & Sons
Language eng
Subject 11 Medical and Health Sciences
1117 Public Health and Health Services
1115 Pharmacology and Pharmaceutical Sciences
Formatted abstract
Clopidogrel has shown benefit in patients with increased risk of cardiovascular diseases. Due to its high acquisition cost and its increased use, this study was conducted to review the use of clopidogrel based on the Food and Drug Administration (FDA)-approved indications and the ST-segment elevation myocardial infarction (STEMI).

This was a cross-sectional study conducted at a tertiary-care, university-affiliated hospital in the Northern part of Thailand. Medical records of patients receiving clopidogrel during January 2005 to February 2006 were reviewed. Baseline characteristics of patients along with specific information regarding the use of clopidogrel were collected. Data were analysed using descriptive statistics.

A total of 191 patients were included in this utilisation review (95 and 96 were inpatient and outpatient, respectively). The use of clopidogrel was deemed appropriate in 82.7% of cases including 72.2% for FDA-approved indications and 10.5% for STEMI. Clopidogrel/aspirin combination was indicated in 93 patients; however, 22 patients received clopidogrel monotherapy. On the contrary, 10 patients received clopidogrel/aspirin combination when only clopidogrel monotherapy was indicated. Moreover, 60% of patients who received clopidogrel monotherapy had no history of aspirin intolerance or recurrent events while on aspirin therapy.

The results showed that the majority of clopidogrel use was deemed appropriate based on FDA-approved indications and for medically justified indication. However, a significant number of patients received clopidogrel instead of aspirin while no aspirin intolerance was documented. Therefore, efforts should be made to promote the appropriate use of this agent to improve patient outcomes.
Keyword clopidogrel
drug use evaluation
utilisation review
Q-Index Code C1
Q-Index Status Provisional Code
Institutional Status Non-UQ

Document type: Journal Article
Sub-type: Article (original research)
Collections: Excellence in Research Australia (ERA) - Collection
School of Public Health Publications
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 1 times in Thomson Reuters Web of Science Article | Citations
Scopus Citation Count Cited 1 times in Scopus Article | Citations
Google Scholar Search Google Scholar
Created: Thu, 24 Dec 2009, 01:07:12 EST by Ms Lynette Adams on behalf of School of Public Health